ACKNOWLEDGEMENT
None
1. Dandana A, Ben
Khelifa S, Chahed H, Miled A, Ferchichi S. Gaucher Disease: Clinical,
Biological and Therapeutic Aspects. Pathobiol J Immunopathol Mol Cell
Biol. 2016;83(1):13–23.
2. Bremova-Ertl T,
Schiffmann R, Patterson MC, Belmatoug N, Billette de Villemeur T,
Bardins S, et al. Oculomotor and Vestibular Findings in Gaucher Disease
Type 3 and Their Correlation with Neurological Findings. Front Neurol.
2017;8:711.
3. Esteban O, Torralba
MA, Olivera S, Martinez M, Montes P, Marco S, et al. New correlations
between ocular parameters and disease severity in Spanish patients with
Gaucher’s disease Type I. PloS One. 2021;16(12):e0260241.
4. Accardo A, Bembi B,
Pensiero S, Perissutti P. Type 3 Gaucher’s disease in a three-year-old
child: saccadic eye movements analysis. J AAPOS Off Publ Am Assoc
Pediatr Ophthalmol Strabismus. 2005 Oct;9(5):501–3.
5. Grabowski GA.
Gaucher disease: gene frequencies and genotype/phenotype correlations.
Genet Test. 1997;1(1):5–12.
6. Charrow J,
Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The
Gaucher registry: demographics and disease characteristics of 1698
patients with Gaucher disease. Arch Intern Med. 2000 Oct
9;160(18):2835–43.
7. Kaplan P, Baris H,
De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M, et al. Revised
recommendations for the management of Gaucher disease in children. Eur J
Pediatr. 2013 Apr;172(4):447–58.
8. Puri RD, Kapoor S,
Kishnani PS, Dalal A, Gupta N, Muranjan M, et al. Diagnosis and
Management of Gaucher Disease in India - Consensus Guidelines of the
Gaucher Disease Task Force of the Society for Indian Academy of Medical
Genetics and the Indian Academy of Pediatrics. Indian Pediatr. 2018 Feb
15;55(2):143–53.
9. Weinreb NJ,
Goker-Alpan O, Kishnani PS, Longo N, Burrow TA, Bernat JA, et al. The
diagnosis and management of Gaucher disease in pediatric patients: Where
do we go from here? Mol Genet Metab. 2022 May;136(1):4–21.
10. Gary SE, Ryan E,
Steward AM, Sidransky E. Recent advances in the diagnosis and management
of Gaucher disease. Expert Rev Endocrinol Metab. 2018
Mar;13(2):107–18.
11. Gupta N, Oppenheim
IM, Kauvar EF, Tayebi N, Sidransky E. Type 2 Gaucher disease: phenotypic
variation and genotypic heterogeneity. Blood Cells Mol Dis. 2011 Jan
15;46(1):75–84.
12. Roshan Lal T,
Sidransky E. The Spectrum of Neurological Manifestations Associated with
Gaucher Disease. Dis Basel Switz. 2017 Mar 2;5(1):10.
13. Wang HP, Wong LC,
Hsu CJ, Hu SC, Chu YJ, Lee WT. Eye motor manifestations in children with
neurometabolic disorders. J Formos Med Assoc Taiwan Yi Zhi. 2022
Apr;121(4):736–48.
14. Hopf S, Pfeiffer
N, Liesenfeld M, Mengel KE, Hennermann JB, Schmidtmann I, et al. A
comprehensive monocentric ophthalmic study with Gaucher disease type 3
patients: vitreoretinal lesions, retinal atrophy and characterization of
abnormal saccades. Orphanet J Rare Dis. 2019 Nov 14;14(1):257.